Royalty Pharma plc

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Royalty Pharma plc
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: United Kingdom
Headquarters city: New York
Headquarters state / province: New York
Headquarters country: United States
Fiscal year end: December
Ticker symbol: RPRX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001802768

Board of directors

Follow this board

Bonnie L. Bassler · Director
Since 2023
Carole Ho · Director
Since 2025
Catherine M. Engelbert · Director
Since 2023
David C. Hodgson · Director
Since 2023
Elizabeth H. Weatherman · Director
Since 2025
Errol B. Desouza · Director
Since 2023
Gregory Norden · Director
Since 2023
Henry A. Fernandez · Director
Since 2023
Mario Germano Giuliani · Director
Since 2023
Pablo G. Legorreta · Director · CEO, Chairman of the Board
Since 2023
Rory B. Riggs · Director
Since 2023
Ted W. Love · Director Overboarded
Since 2023
Vlad Coric · Director
Since 2025

Chief executives

Pablo G. Legorreta · CEO, Chairman of the Board

Dates unknown

Director election results

Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

12 of this board's directors also sit on 19 other boards. 14 are in the same sector.

Shared director Other board Same sector +3 more in the list below

Alector Inc. Same sector
via Errol B. Desouza
Alignment Healthcare Inc.
via David C. Hodgson
Beam Therapeutics Inc. Same sector
via Carole Ho
Biohaven Ltd. Same sector
via Vlad Coric
Cibus Inc.
via Rory B. Riggs
Gilead Sciences Inc. Same sector
via Ted W. Love
Insulet Corporation Same sector
via Elizabeth H. Weatherman
Jazz Pharmaceuticals plc Same sector
via Ted W. Love
Korsana Biosciences Inc. Same sector
via Errol B. Desouza
Lisata Therapeutics Inc. Same sector
via Ted W. Love
MSCI Inc.
via Henry A. Fernandez
McDonald's Corporation
via Catherine M. Engelbert
Praxis Precision Medicines Inc. Same sector
via Gregory Norden
ProKidney Corp. Same sector
via Pablo G. Legorreta
Regeneron Pharmaceuticals Inc. Same sector
via Bonnie L. Bassler
Structure Therapeutics Inc. Same sector
via Ted W. Love
TriNet Group Inc.
via David C. Hodgson
Veradermics Incorporated Same sector
via Vlad Coric
Zoetis Inc. Same sector
via Gregory Norden

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $92,822,021; 74 sales by 5 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 6, 2026	Coyne Terrance P. Officer (EVP & CFO)	Derivative conversion	+150,000	—	—
Nov 6, 2026	Urist Marshall Officer (EVP, Research & Investments)	Derivative conversion	+150,000	—	—
Nov 6, 2026	Coyne Terrance P. Officer (EVP & CFO)	Derivative conversion	+100,000	—	—
Nov 4, 2026	Coyne Terrance P. Officer (EVP & CFO)	Grant or award	+7,122	—	—
Nov 4, 2026	Christopher Hite Officer (EVP & Chairman, Partnering)	Grant or award	+7,122	—	—
Nov 4, 2026	Pablo G. Legorreta Director, Officer (CEO, Chairman of the Board)	Grant or award	+42,209	—	—
Nov 4, 2026	Urist Marshall Officer (EVP, Research & Investments)	Grant or award	+5,341	—	—
Oct 5, 2026	Urist Marshall Officer (EVP, Research & Investments)	Open-market sale	−4,126	$57.10	$235,595
Sep 30, 2026	Bonnie L. Bassler Director	Grant or award	+642	$58.41	$37,499
Sep 28, 2026	Urist Marshall Officer (EVP, Research & Investments)	Open-market sale	−4,126	$57.88	$238,813
Sep 22, 2026	Christopher Hite Officer (EVP & Chairman, Partnering)	Open-market sale	−96,073	$58.51	$5,621,231
Sep 22, 2026	Christopher Hite Officer (EVP & Chairman, Partnering)	Open-market sale	−3,927	$58.93	$231,418
Aug 19, 2026	Christopher Hite Officer (EVP & Chairman, Partnering)	Gift	−16,800	—	—
Aug 18, 2026	Christopher Hite Officer (EVP & Chairman, Partnering)	Open-market sale	−100,000	$59.97	$5,997,000
Aug 13, 2026	Coyne Terrance P. Officer (EVP & CFO)	Open-market sale	−9,230	$58.59	$540,786

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Royalty Pharma plc

Who is the CEO of Royalty Pharma plc?

Pablo G. Legorreta is Royalty Pharma plc's CEO, Chairman of the Board.

How many directors are on Royalty Pharma plc's board?

Royalty Pharma plc's board has 13 directors: Bonnie L. Bassler, Carole Ho, Catherine M. Engelbert, David C. Hodgson, Elizabeth H. Weatherman, Errol B. Desouza, Gregory Norden, Henry A. Fernandez, Mario Germano Giuliani, Pablo G. Legorreta and 3 others.

Are Royalty Pharma plc insiders buying or selling shares?

Over the last 12 months, Royalty Pharma plc insiders made no open-market purchases and sold $92.8 million of shares in 74 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Royalty Pharma plc connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="royalty-pharma-plc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.